Hepatobiliary disease in inflammatory bowel disease

Gastroenterology Clinics of North America

Volumn 31, Issue 1, 2002, Pages 329-345

  Ahmad, Jawad ^a   Slivka, Adam ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; IMMUNOMODULATING AGENT; PREDNISONE; URSODEOXYCHOLIC ACID;

BILE DUCT CARCINOMA; CHOLANGIOGRAPHY; CHOLELITHIASIS; CLINICAL FEATURE; COLORECTAL CANCER; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC THERAPY; ENTERITIS; HEPATOBILIARY DISEASE; HUMAN; LIVER ABSCESS; LIVER TRANSPLANTATION; PATHOGENESIS; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; BILIARY TRACT DISEASE; LIVER DISEASE; SCLEROSING CHOLANGITIS;

BILIARY TRACT DISEASES; CHOLANGITIS, SCLEROSING; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES;

EID: 0035986154     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(01)00020-6     Document Type: Article

References (131)

1. Primary sclerosing cholangitis: A long-term follow-up study
2. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis
3. Do primary sclerosing cholangitis (PSC) patients who express HLA-DR4 haplotype have a more rapidly progressive disease?
4. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis associated cholangiocarcinoma
5. Primary sclerosing cholangitis: Resect, dilate or transplant?
6. Cholelithiasis and urolithiasis in Crohn's disease
7. Oral budesonide in the treatment of primary sclerosing cholangitis
8. Oral nicotine in treatment of primary sclerosing cholangitis: A pilot study
9. Time course of histological progression in primary sclerosing cholangitis
10. Primary sclerosing cholangitis
11. Serum autoantibodies in patients with primary sclerosing cholangitis
12. Bone disease in patients with primary sclerosing cholangitis: Prevalence, severity and prediction of progression
13. Gallstones in inflammatory bowel disease
14. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis
15. Clinical course and management of inflammatory bowel disease after liver transplantation
16. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study
17. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis
18. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis
19. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis
20. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development
21. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis
22. Enterohepatic cycling of bilirubin: A putative mechanism for pigment gallstone formation in ileal Crohn's disease
23. Cytokine production from colonic T cells in patients with ulcerative colitis with and without primary sclerosing cholangitis
24. Primary sclerosing cholangitis and ulcerative colitis: Indicator of increased neoplastic potential
25. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis
26. Primary biliary cirrhosis and ulcerative colitis
27. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
28. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis
29. Liver disease and gallstones in regional enteritis
30. Oral vancomycin: Treatment of primary sclerosing cholangitis in children with inflammatory bowel disease
31. Portal vein thrombosis in a complicated case of Crohn's disease
32. Expression of CD44 on bile ducts in primary sclerosing cholangitis and primary biliary cirrhosis
33. A shared and unique epitope(s) on human colon, skin and biliary epithelium detected by a monoclonal antibody
34. End-stage primary sclerosing cholangitis: CT findings of hepatic morphology in 36 patients
35. Lithogenic bile in patients with ileal dysfunction
36. Primary sclerosing cholangitis: Liver transplantation or biliary surgery
37. Biliary cholesterol and lithogenicity of bile in patients after ileal resection
38. Amino acid substitutions at positions 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis
39. Natural history and prognostic variables in primary sclerosing cholangitis
40. Natural history and prognosis in primary sclerosing cholangitis
41. Pigment gallstones in Crohn's disease
42. Primary sclerosing cholangitis: Evaluation with MR cholangiography-a case-control study
43. Orthotopic liver transplantation for primary sclerosing cholangitis: A 12-year single center experience
44. Liver transplantation for primary sclerosing cholangitis
45. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis
46. Fibrous and obliterative cholangitis in liver allografts: Evidence of recurrent primary sclerosing cholangitis?
47. Gallstones in patients with disorders of the terminal ileum and disturbed bile salt metabolism
48. Gallstones after ileostomy and ileal resection
49. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis
50. Pathogenesis of gall stones in Crohn's disease: An alternative explanation
51. Primary sclerosing cholangitis: MR imaging features
52. Microsatellite instability is absent in liver and biliary mucosa of patients with primary sclerosing cholangitis
53. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: A larger series and recommendations for treatment
54. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: Ileal pouch-anal anastomosis versus Brooke ileostomy
55. Primary biliary cirrhosis and chronic pancreatitis in a patient with ulcerative colitis
56. Biliary tract calculi in primary sclerosing cholangitis
57. Variant forms of cholestatic disease involving small bile ducts in adults
58. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis
59. A revised natural history model for primary sclerosing cholangitis
60. A double blind controlled trial of oral-pulse methotrexate therapy on the treatment of primary sclerosing cholangitis
61. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: A population-based study
62. Ulcerative colitis associated with primary biliary cirrhosis
63. Ursodeoxycholic acid therapy in hepatobiliary disease
64. A prospective controlled study comparing brush and bile exfoliative cytology for diagnosing bile duct strictures
65. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease
66. Bile composition in patients with ileal resection due to Crohn's disease
67. Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease
68. Prospective trial of penicillamine in primary sclerosing cholangitis
69. Endoscopic therapy in sclerosing cholangitis
70. Primary sclerosing cholangitis
71. Primary biliary cirrhosis associated with ulcerative colitis
72. Biliary tract disease in rats with experimental small bowel bacterial overgrowth
73. Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth
74. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study
75. The Mayo PSC/UDCA study group: Ursodiol for primary sclerosing cholangitis
76. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation
77. Cholelithiasis in inflammatory bowel disease: A case control study
78. The syndrome of primary sclerosing cholangitis
79. Primary sclerosing cholangitis
80. A prospective evaluation of cytology from biliary strictures
81. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis
82. Orthotopic liver transplantation for primary sclerosing cholangitis
83. Surgical aspects of sclerosing cholangitis
84. Non-operative dilation of dominant strictures in primary sclerosing cholangitis
85. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases
86. A survey of cytomegalovirus DNA in primary sclerosing cholangitis liver tissue using a sensitive polymerase chain reaction based assay
87. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis
88. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis
89. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants
90. Portal vein thrombosis associated with active ulcerative colitis: Percutaneous transhepatic recanalization
91. Crohn's disease presenting as pyogenic liver abscess with review of previous case reports
92. Liver transplantation for sclerosing cholangitis
93. Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation
94. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis
95. Colchicine treatment of primary sclerosing cholangitis
96. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis
97. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis
98. Sclerosing cholangitis and biliary tract calculi-primary or secondary?
99. Immunohistochemical analysis of inflammation in primary sclerosing cholangitis
100. Four years experience with short term stenting in primary sclerosing cholangitis
101. Value of brush cytology for dominant strictures in primary sclerosing cholangitis
102. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease
103. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: A prospective study
104. Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: A study of 65 patients with bile duct strictures
105. Hepatobiliary manifestations of inflammatory bowel disease
106. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
107. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease
108. Primary sclerosing cholangitis: MR imaging findings with pathologic correlation
109. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease
110. Cholangiocarcinoma complicating primary sclerosing cholangitis
111. Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells
112. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis
113. Neutrophil antibodies: A genetic marker in primary sclerosing cholangitis and ulcerative colitis
114. Bile acids in liver disease associated with inflammatory bowel disease
115. Phenotypic and functional characteristics of colinic lymphocytes isolated from patients with primary sclerosing cholangitis and inflammatory bowel disease
116. Cholangiocarcinoma in sclerosing cholangitis: Role of liver transplantation
117. Chronic ulcerative colitis: Incidence and prevalence in a community
118. A typical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins
119. Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines
120. Effectiveness of combined anticoagulant therapy for extending portal vein thrombosis in Crohn's disease: Report of a case
121. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis
122. Liver abscess in Crohn's disease
123. Budesonide or prednisone in combination with ursodeoxcholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study
124. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
125. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis
126. Ulcerative colitis, primary biliary cirrhosis, and chronic pancreatitis: Coincident or coexistent?
127. Immunological analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis
128. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease
129. Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis
130. Clinicopathologic features of the syndrome of primary sclerosing cholangitis
131. Current concepts in primary sclerosing cholangitis